603983 丸美生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.6327.36810.1567.9395.554
总资产报酬率 ROA (%)3.3635.1107.1806.0704.435
投入资产回报率 ROIC (%)3.9325.9508.2916.9935.114

边际利润分析
销售毛利率 (%)73.64774.28673.70170.69468.396
营业利润率 (%)11.0228.57412.82714.34811.973
息税前利润/营业总收入 (%)10.7178.03012.34413.60111.199
净利润/营业总收入 (%)9.4387.13311.52812.4739.669

收益指标分析
经营活动净收益/利润总额(%)66.31882.64394.45761.64978.394
价值变动净收益/利润总额(%)32.5249.4635.00236.14915.886
营业外收支净额/利润总额(%)-0.251-0.297-0.074-0.710-0.366

偿债能力分析
流动比率 (X)1.9431.8651.8512.5043.347
速动比率 (X)1.7751.6701.7132.3343.120
资产负债率 (%)25.80326.42931.92223.24320.555
带息债务/全部投入资本 (%)14.39914.67422.41412.6079.765
股东权益/带息债务 (%)590.080577.917344.168688.049916.806
股东权益/负债合计 (%)282.885273.207209.176323.331378.829
利息保障倍数 (X)-38.645-15.485-26.085-21.034-15.332

营运能力分析
应收账款周转天数 (天)3.4794.2534.4257.91113.222
存货周转天数 (天)88.28991.66990.20189.25995.422